Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Abstract Background Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients...

Full description

Bibliographic Details
Main Authors: Anthony B. El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K. Abou-Alfa
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
Cabozantinib
Child–Pugh B
Hepatocellular carcinoma
Online Access:https://doi.org/10.1186/s12885-022-09453-z

Internet

https://doi.org/10.1186/s12885-022-09453-z

Similar Items